SCHEMBL4912299

SCHEMBL4912299

CCOC(=O)N[CH]c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
RAB9A P51151 6/20 0.54
NPC1 O15118 4/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
LMNA P02545 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
GAA P10253 1/20 0.53
ALDH1A1 P00352 2/20 0.51
POLB P06746 2/20 0.51
MAPT P10636 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HTT P42858 1/20 0.48
HPGD P15428 1/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
PPID Q08752 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922122 0.86 LMNA (0.50) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL3930322 0.83 TDP1 (0.58) RAB9ANPC1SMN1; SMN2LMNAL3MBTL1
SCHEMBL10644080 0.83 RAB9A (0.58) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL9269436 0.83 RAB9A (0.58) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL3934013 0.82 NPC1 (0.53) RAB9ANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL3928127 0.82 LMNA (0.56) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL94681 0.81 ALDH1A1 (0.51) RAB9ANPC1SMN1; SMN2LMNAGAA
SCHEMBL6208323 0.79 CHRM1 (0.49) MEN1KMT2ALMNAGAAALDH1A1
SCHEMBL11563395 0.78 MEN1 (0.37) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL8554280 0.77 SMN1; SMN2 (0.57) MEN1KMT2ARAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PFIZER INC. 2008-08-21 US disclosed
EP-1866317-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2007-12-19 EP disclosed
WO-2006103555-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PF4, TBXA2R, P2RY4 MEN1 4406/4885KMT2A 2100/4885RAB9A 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.